AI Article Synopsis
- This review explores the combination of tumor ablation therapies with immunotherapy for treating advanced respiratory and digestive tumors, like non-small cell lung cancer (NSCLC) and liver cancer.
- It discusses the limitations of traditional treatment methods and the benefits of minimally invasive ablation techniques, such as radiofrequency ablation (RFA) and microwave ablation (MWA), alongside immune checkpoint inhibitors.
- The review emphasizes the potential for combined therapies to enhance clinical outcomes and outlines future research directions for improving treatment protocols, understanding molecular mechanisms, and making advanced therapies more accessible to patients.
Article Abstract
This review examines combining tumor ablation therapy with immunotherapy for respiratory and digestive system tumors, particularly NSCLC and liver cancer. Despite advancements in traditional methods, they face limitations in advanced-stage tumors. Ablation techniques like RFA, MWA, and cryoablation offer minimally invasive options, while immune checkpoint inhibitors enhance the immune system's tumor-fighting ability. This review highlights their synergistic effects, clinical outcomes, and future research directions, including optimizing protocols, exploring new combinations, uncovering molecular mechanisms, advancing precision medicine, and improving accessibility. Combined therapy is expected to improve efficacy and patient outcomes significantly.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11382172 | PMC |
| http://dx.doi.org/10.1016/j.heliyon.2024.e36388 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!